A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MARITIME-2)
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MARITIME-2)
The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.
Inclusion Criteria:
Exclusion Criteria:
Skokie, Illinois 60077, United States
CABA, Buenos Aires 1120, Argentina
CABA, Buenos Aires C1060ABN, Argentina
CABA, Buenos Aires C1407GTN, Argentina
CABA, Buenos Aires C1425AGC, Argentina
CABA, Buenos Aires C1426ABP, Argentina
Ciudad Autonoma de Buenos Aires, Buenos Aires C1056ABI, Argentina
Ciudad Autonoma de Buenos Aires, Buenos Aires C1061AAT, Argentina
Pleven, 5801, Bulgaria
Sofia, 1407, Bulgaria
Halifax, Nova Scotia B3H 2Y9, Canada
North York, Ontario M6B 3H7, Canada
Pribram VIII, 261 01, Czechia
Kitakyusyu-shi, Fukuoka 807-0072, Japan
Aki-gun, Hiroshima 735-8585, Japan
Tsuchiura-shi, Ibaraki 300-0835, Japan
Kashiwara-shi, Osaka 582-0005, Japan
Meguro-ku, Tokyo 153-0053, Japan
Mitaka-shi, Tokyo 181-0013, Japan
Ansan-si, Gyeonggi-do, 15355, South Korea
Seongnam-si, Gyeonggi-do, 13620, South Korea
Leicester, LE5 4PW, United Kingdom